Wednesday, November 5, 2014

Afrezza, the Inhalable Insulin

Here is the Joslin Diabetes Center's report on Afrezza, the inhalable
insulin. It is FDA approved, and it appears to be safe. It may prove
to be valuable to people who are hesitant to use insulin injections, but
it is not yet approved for children.
This product is intended to be used as a supplement, so you cannot
stop injections altogether. It does not allow users to fine tune their
insulin doses. Peak activity occurs in 12-15 minutes, and it leaves the system rather quickly.
"Afrezza is not recommended for patients who smoke, have asthma or chronic lung disease. If you’re at high risk for Diabetic Ketoacidosis, (DKA) you probably shouldn’t start this new inhalable insulin at all. During the clinical trials, there was an increased rate of DKA."

No comments:

Post a Comment